The addition of metformin to standard therapy for lung adenocarcinoma patients significantly improves patient outcome [29], while phenformin inhibits tumor growth and angiogenesis in preclinical models of Kras-driven NSCLC [30]. This evidence concerns the gene KRAS and lung adenocarcinoma.